AXIM BIOTECHNOLOGIES, INC. (AXIM)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2023, AXIM BIOTECHNOLOGIES, INC. reported revenue of $39.5K, up 345.3% from the prior year. The company ran a net loss, with a net margin of -20395.0%. It held $4.12M in total assets against $11.78M in total liabilities.
Key ratios (FY2023)
-6961.0%
Operating margin
-20395.0%
Net margin
+345.3%
Revenue growth (YoY)
| Metric (FY) | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.5K | $8.9K | $60.5K | $0 | $799.5K | $195.6K | $47.6K | $47.1K | $49.1K | $0 |
| Cost of Revenue | — | — | — | $0 | $0 | $8.5K | $42.9K | $154.1K | — | — |
| Gross Profit | — | — | — | $0 | $0 | $187.1K | $4.7K | -$107.1K | -$1.2K | $0 |
| Operating Income | -$2.75M | -$4.65M | -$13.97M | -$4.95M | -$3.11M | -$5.04M | -$3.15M | -$3.76M | -$10.05M | -$505.7K |
| Net Income | -$8.06M | -$6.24M | -$16.03M | -$6.41M | -$6.45M | -$6.75M | -$4.17M | -$5.81M | -$10.09M | -$582.9K |
| EPS (Diluted) | $-0.04 | $-0.04 | $0.12 | $-0.06 | $-0.10 | — | — | — | — | — |
| Total Assets | $4.12M | $4.21M | $5.32M | $11.31M | $1.69M | $2.09M | $2.19M | $1.45M | $1.26M | $738.5K |
| Total Liabilities | $11.78M | $9.04M | $7.66M | $9.75M | $8.45M | $8.17M | $8.48M | $3.82M | $2.96M | $1.32M |
| Shareholders' Equity | -$7.66M | -$4.83M | -$2.34M | $1.57M | -$6.76M | — | — | -$2.37M | -$1.70M | -$580.7K |
| Cash & Equivalents | — | $47.3K | $453.0K | $457.2K | $511.6K | $1.81M | $2.06M | $713.3K | $134.2K | $661.1K |
| Operating Cash Flow | -$1.03M | -$2.04M | -$2.49M | -$3.22M | -$5.04M | — | — | -$1.29M | -$1.54M | -$339.0K |
| Capital Expenditures | $0 | $8.7K | $40.5K | $97.3K | — | — | — | $0 | -$16.8K | $0 |
| Shares Outstanding | 245.93M | 192.44M | 138.10M | 125.33M | 64.85M | 59.58M | 54.56M | 52.51M | 39.63M | 33.00M |